Oragenics, Inc.

204 articles about Oragenics, Inc.

• Oragenics Prices $5.25 Million Common Stock Offering - Nov 20, 2020

  11/20/2020

  Oragenics, Inc., a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced the pricing of an underwritten public offering of 14,189,189 shares of its common stock at a price to the public of $0.37 per share.

• Organics Announces Proposed Underwritten Public Offering - Nov 19, 2020

  11/19/2020

  Oragenics, Inc. a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, announced that it has commenced a proposed underwritten public offering of common stock of the Company.

• FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine

  10/6/2020

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration (“FDA”) that it is in broad agreement with the Company’s planned approach to clinical development of its SARS-CoV-2 vaccine, Terra CoV-2. As a r

• Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

  9/28/2020

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) provides an update on U.S. federal government and other funding options the Company is pursuing in order to advance its SARS-CoV-2 vaccine, Terra CoV-2. Oragenics has been informed by the Biomedical Advanced Research and Development Authority (“BARDA”) of BARDA’s determination not to enter into negotiation with the Company. While BARDA noted the Com

• Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference

  9/11/2020

  Oragenics, Inc. (NYSE American: OGEN) , a biopharmaceutical company dedicated to the development and commercialization of a vaccine candidate to combat the novel coronavirus pandemic (commonly referred to as COVID-19) today announces that Alan Joslyn, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference (the “Conference”). The Conference is to

• Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine

  8/20/2020

  Avid Well Positioned to Meet Significant Scale-Up Requirements for NIH-Licensed SARS-CoV-2 Spike Protein Vaccine Candidate

• Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

  7/22/2020

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces that the National Institutes of Health (the “NIH”) created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19.

• Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program

  7/10/2020

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or “the Company”) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients. While working with Aragen Bioscience, a leading contract research

• Oragenics, Inc. to Present at the June 2020 Virtual Summer Investor Summit

  6/4/2020

  Oragenics, Inc. (NYSE American: OGEN) , announced today that Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc., will give a virtual corporate presentation at the June 2020 Virtual Summer Investor Summit taking place online from June 9th to 12th, 2020. The presentation will be held on Wednesday, June 10, 2020 at 2:10 pm ET, fo

• Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a SARS-CoV-2 (COVID 19) Vaccine Candidate

  5/19/2020

  Oragenics, Inc. (NYSE American: OGEN) , (the “Company” or “Oragenics”), today announced, that through its wholly-owned subsidiary, Noachis Terra, it has entered into an agreement with Aragen Bioscience, a leading contract research organization focused on accelerating pre-clinical biologics product development, to advance TerraCov2 the Company’s SARS CoV-2 vaccine candidate. Under the terms of the ag

• Oragenics Announces New Member of the Board of Directors

  5/4/2020

  Oragenics, Inc., announced that it has increased the size of its board of directors and appointed Ms. Kim Murphy to the board, effective May 1, 2020.

• Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”

  5/4/2020

  Oragenics, Inc.,, announced its acquisition of Noachis Terra Inc., following its entry into a stock purchase agreement, to develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus, the root cause of coronavirus disease 2019.

• Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer

  4/15/2020

  Oragenics, Inc. announced that early top-line results of the company’s Phase 2 clinical trial of AG013 in oral mucositis in chemoradiation in head and neck cancer patients did not demonstrate statistical significance on the primary endpoint of severe oral mucositis duration when compared to placebo.

• Oragenics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

  2/7/2020

  Feb. 7, 2020 15:24 UTC Oragenics, Inc. to Present at the 22 nd Annual BIO CEO & Investor Conference TAMPA, Fla.--( BUSINESS WIRE )-- Oragenics, Inc. (NYSE American: OGEN) , a leader in the development of effective treatments for oral mucositis and new antibiotics against infectious diseases, announced today that Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc., will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference being held on Feb

• Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019

  12/3/2019

  Dr. Joslyn will provide an overview of the company’s business model and growth strategy and will be available for one-on-one meetings.

• Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

  12/2/2019

  The ongoing Phase 2 trial is a double-blind, placebo-controlled, two-arm, multi-country, multi-center trial, in which 200 patients have been randomized in a 1:1 ratio to receive either AG013 or a placebo.

• Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog

  11/15/2019

  Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of the outcome of the a specific chemical synthesis of the bicyclic C/D ring of an analog of the company’s lantibiotic compound, Mutacin 1140.

• Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and Applications

  11/11/2019

  Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the company’s Senior Vice President of Discovery Research, Martin Handfield, MS, Ph.D., will be a featured speaker at the inaugural International Conference on Microbial Research and Applications (MicroBiome 2019).

• Oragenics, Inc. to Present at the BIO Investor Forum

  10/22/2019

  The BIO Investor Forum will be held October 22-23, 2019.

• Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019

  9/30/2019

  Oragenics, Inc. announces initial data from its ongoing Phase 2, placebo-controlled, clinical trial of AG013 in oral mucositis presented in a poster session at the European Society for Medical Oncology Congress 2019 in Barcelona, Spain.